OG-L002 is primarily used in biochemical and pharmaceutical research as a potent and selective inhibitor of the menin-MLL (mixed lineage leukemia) protein-protein interaction. This interaction plays a critical role in certain types of leukemia, particularly MLL-rearranged (MLL-r) leukemias, which are aggressive forms of acute leukemia affecting both children and adults. By disrupting the menin-MLL binding, OG-L002 effectively suppresses the expression of key oncogenes such as HOXA9 and MEIS1, leading to inhibition of leukemia cell proliferation and induction of apoptosis in cancer cells. Due to this mechanism, OG-L002 serves as a valuable tool compound in studies aimed at understanding leukemogenesis and evaluating targeted therapeutic strategies. Its high selectivity and cellular permeability make OG-L002 suitable for in vitro and in vivo research models, including cell-based assays and animal studies investigating the efficacy of menin inhibitors. It is widely used in drug discovery programs focused on epigenetic regulators and targeted cancer therapies, particularly for hematological malignancies.